Media
7 News Australia
Australian company Imugene; saving lives using a cancer eating virus
SmallCaps (video)
CEO Leslie Chong joins Small Caps to discuss the progress of the Phase 1 MAST trial of our novel cancer-killing virus CF33-hNIS – known as VAXINIA.
Proactive Investors (video)
CEO Leslie Chong joins Proactive in the studio to discuss the results from the Phase 1 MAST (metastatic advanced solid tumours) trial evaluating the safety of novel cancer-killing virus CF33-hNIS (VAXINIA).
Proactive Investors
Imugene presents CF33-hNIS oncolytic virus study details at ASCO-GI Cancers Symposium
Proactive Investors
Imugene plans Phase 1 VAXINIA MAST trial expansion to target bile duct cancer
Stockhead
ASX Health Stocks: Imugene gains on positive early signs from Phase 1 trial
SmallCaps
Imugene reports positive outcomes in novel virus trial against advanced cancers
Proactive Investors
Imugene receives positive early results, including a ‘complete response’, in Phase 1 VAXINIA study
Kalkine Media
How far have Imugene’s (ASX: IMU) four novel platforms progressed in the fight against cancer?
Biotech Daily
Dr Boreham’s Crucible: Imugene
Stockhead